Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 64 out of 100. How common it is

Topic: Risk, prevention and care in population studies

Plain-language summary

One million nine hundred twenty-five thousand, five hundred sixty-three individuals were included across the four databases with a median follow-up ranging from 5.6 to 8.4 years. Compared to ACEI, initiation with ARB was associated with a reduced risk of incident all-cause dementia [hazard ratio (HR): 0.92, 95% confidence interval (CI): 0.89-0.94] and VaD (HR 0.87, 95% CI 0.78-0.96) but not AD. This is the largest multinational cohort study conducted to date investigating different classes of antihypertensive drugs and the risk of incident dementia. When initiating antihypertensives, physicians and patients should consider the reduced risk of all-cause dementia and VaD with ARB compared with ACEI in their risk-benefit assessment.

What this study adds

Evidence grade: High

This is a pooled review. In this large multinational cohort, starting an ARB was associated with a reduced risk of all-cause dementia and vascular dementia compared with starting an ACEI, but not with a reduced risk of Alzheimer's disease. Reported effect size: HR 0.87.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Cheung, E. C. L., Adesuyan, M., Szilcz, M., Ellett, L. M. K., Shah, S. H., Jani, Y. H., et al. (2025). Antihypertensive drug classes and risk of incident dementia: a multinational population-based cohort study. Age and Ageing. https://doi.org/10.1093/ageing/afaf121

Vancouver

Cheung ECL, Adesuyan M, Szilcz M, Ellett LMK, Shah SH, Jani YH, et al. Antihypertensive drug classes and risk of incident dementia: a multinational population-based cohort study. Age and Ageing. 2025. doi:10.1093/ageing/afaf121. PMID: 40413804.

BibTeX

@article{cheung2025-40413804,
  author  = {Cheung, Edmund Chi Lok and Adesuyan, Matthew and Szilcz, Máté and Ellett, Lisa M. Kalisch and Shah, Sonia H and Jani, Yogini Hariprasad and Hägg, Sara and Pratt, Nicole L. and others},
  title   = {{Antihypertensive drug classes and risk of incident dementia: a multinational population-based cohort study}},
  journal = {Age and Ageing},
  year    = {2025},
  doi     = {10.1093/ageing/afaf121},
  pmid    = {40413804},
  url     = {https://doi.org/10.1093/ageing/afaf121}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In this large multinational cohort, starting an ARB was associated with a reduced risk of all-cause dementia and vascular dementia compared with starting an ACEI, but not with a reduced risk of Alzheimer's disease. The authors suggest physicians and patients consider this in risk-benefit assessment when initiating antihypertensives.

Study details

How this study scored 64/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 12 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 3 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 2 of 5; Impact for its field and year 4 of 6; Cited by studies here 1 of 6; Still being cited 1 of 4; Senior author's track record 2 of 4; Institution's track record 2 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 64 of 100.64 of 100 points earned36 not earned

Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. Scored zero for sample size and studied in people because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Age and Ageing)
Journal's citation record 2 / 4 Age and Ageing: journal h-index 231 (OpenAlex, 2026-10-29)
Study design 12 / 12 A meta-analysis pooling many studies
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited 2 / 7 Cited 14 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 4.7 citations a year over 3 year(s) since 2025
Impact for its field and year 4 / 6 Cited 8.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 1 / 4 Cited 14 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Celine Sze Ling Chui: h-index 39 (OpenAlex, whole career)
Institution's track record 2 / 3 University College London: institution h-index 2,029 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 11 institution(s) in 6 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40413804)
Free to read 2 / 2 Free to read
Total 64 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in How common it is from nearby years

Also tagged “biobank”

1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on How common it is

See all studies in How common it is →